New York, December 03, 2013 /Accesswire/ - Market Buzz Report, a leading penny stock newsletters provider, issues major news alert for XOMA Corp. (NASDAQ:XOMA), Keryx Biopharmaceuticals (NASDAQ:KERX), Oncomed Pharmaceuticals Inc(NASDAQ:OMED), Tesla Motors Inc(NASDAQ:TSLA).
XOMA Corp. (NASDAQ:XOMA) shares climbed 22.18% to
$5.84. The company announced John Varian, the company's Chief Executive
Officer, is scheduled to present at the 25th Annual Piper Jaffray Healthcare
Conference on December 4, 2013, at 2:00 p.m. EST, at The New York Palace Hotel.
Free Urgent Insider Catalyst Report For XOMA Available Here: http://marketbuzzreport.com/index.php?code=XOMA (Or Copy and paste the URL into your browser)
Additionally, the company on Nov. 20 announced that the United States Patent and Trademark Office has awarded it U.S. patent no. 8,584,349, entitled "Flexible Manufacturing System." This patent relates to modular, flexible manufacturing facilities. The patent is directed to a flexible system of movable manufacturing bays, adapted to easily and quickly connect to a central supply of utilities such as air, water, and electricity.
Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 5.04% to $14.59. The company on Nov. 8 announced preliminary, unaudited data from an ongoing 48-week safety extension study of Zerenex(TM) (ferric citrate coordination complex) the Company's drug candidate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Only patients who had participated in, and successfully completed the 58-week, long-term Phase 3 study were eligible for enrollment into this safety extension study. This 48-week, open-label extension (OLE) study, which is not a regulatory requirement, is being conducted in 35 sites in the United States. The study commenced enrollment in August 2012 and is anticipated to be completed in the first half of 2014.
Free Urgent Insider Catalyst Report For KERX Available Here: http://marketbuzzreport.com/index.php?code=KERX (Or Copy and paste the URL into your browser)
Oncomed Pharmaceuticals Inc(NASDAQ:OMED) announces a development and commercialization agreement with Celgene (CELG). The deal includes demcizumab and "up to six anti-cancer stem cell product candidates."OMED gets $177.25M upfront ($22.25M equity investment).OMED also keeps "global co-development and U.S. co-commercialization rights for five of the six anti-CSC product candidates with 50/50 U.S. profit sharing, and royalties to be received in other territories."CELG has an exclusive option on demcizumab subsequent to which OMED will "co-develop [the drug and] share global development costs on a 1/3 OMED and 2/3 CELG basis."
Free Urgent Insider Catalyst Report For OMED Available Here: http://marketbuzzreport.com/index.php?code=OMED (Or Copy and paste the URL into your browser)
Tesla Motors Inc(NASDAQ:TSLA) says the German Federal Motor Transport has cleared the EV automaker of any manufacturing-related defects for the Model S.Jefferies thinks the positive review in Germany bodes well that Tesla will avoid a safety recall in the U.S. as well.
Free Urgent Insider Catalyst Report For TSLA Available Here: http://marketbuzzreport.com/index.php?code=TSLA (Or Copy and paste the URL into your browser)
USMarketBuzz.com is an investment community that focuses on MicroCap Securities. USMarketBuzz.com is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit http://www.USMarketBuzz.com/ for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.USMarketBuzz.com/.
Follow us on Facebook: https://www.facebook.com/usmarket.buzz
Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126 (SMS alerts are free, however data rates may apply, check your wireless plan for details.).
Leave a comment...